Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway

References

• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075.
   PubMed Web of Science ®Google Scholar
• Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159(1):335–349.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–387.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Kleeff J, Michl P, et al. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333–348.
   PubMed Web of Science ®Google Scholar
• Bertolini F, Sukhatme VP, Bouche G. Drug repurposing in oncology-patient and health systems opportunities. Nat Rev Clin Oncol. 2015;12(12):732–742.
   PubMed Web of Science ®Google Scholar
• Udumyan R, Montgomery S, Fang F, et al. Beta-blocker drug use and survival among patients with pancreatic adenocarcinoma. Cancer Res. 2017;77(13):3700–3707.
   PubMed Web of Science ®Google Scholar
• Beg MS, Gupta A, Sher D, et al. Impact of concurrent medication use on pancreatic cancer survival-SEER-medicare analysis. Am J Clin Oncol. 2018;41(8):766–771.
   PubMed Web of Science ®Google Scholar
• Cerullo M, Gani F, Chen SY, et al. Impact of angiotensin receptor blocker use on overall survival among patients undergoing resection for pancreatic cancer. World J Surg. 2017;41(9):2361–2370.
   PubMed Web of Science ®Google Scholar
• Mc Menamin ÚC, Murray LJ, Cantwell MM, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control. 2012; (2):221–230.
   PubMed Web of Science ®Google Scholar
• Jian-Yu E, Graber JM, Lu SE, et al. Effect of metformin and statin use on survival in pancreatic cancer patients: a systematic literature review and meta-analysis. CMC. 2018;25(22):2595–2607.
   PubMed Web of Science ®Google Scholar
• Tamburrino D, Crippa S, Partelli S, et al. Statin use improves survival in patients with pancreatic ductal adenocarcinoma: a meta-analysis. Dig Liver Dis. 2020;52(4):392–399.
   PubMedGoogle Scholar
• Reni M, Dugnani E, Cereda S, et al. (Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an open-label, randomized phase II trial. Clin Cancer Res. 2016;22(5):1076–1085.
   PubMed Web of Science ®Google Scholar
• Kordes S, Pollak MN, Zwinderman AH, et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2015;16(7):839–847.
   PubMed Web of Science ®Google Scholar
• Braghiroli MI, de Celis Ferrari AC, Pfiffer TE, et al. Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas. Ecancermedicalscience. 2015;9:563.
   PubMed Web of Science ®Google Scholar
• Nakai Y, Isayama H, Ijichi H, et al. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Invest New Drugs. 2013;31(5):1294–1299.
   PubMed Web of Science ®Google Scholar
• Hong JY, Nam EM, Lee J, et al. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. Cancer Chemother Pharmacol. 2014;73(1):125–130.
   PubMed Web of Science ®Google Scholar
• Pantziarka P, Verbaanderd C, Sukhatme V, et al. ReDO_DB: the repurposing drugs in oncology database. Ecancermedicalscience. 2018;12:886.
   PubMed Web of Science ®Google Scholar
• Andreassen BK, Støer NC, Martinsen JI, et al. Identification of potential carcinogenic and chemopreventive effects of prescription drugs: a protocol for a Norwegian registry-based study. BMJ Open. 2019;9(4):e028504.
   PubMed Web of Science ®Google Scholar
• ATC Structure and principles [Internet]. WHO Collaborating Centre for Drug Statistics Methodology. Geneva (Switzerland): WHO; 2018 [cited 2020 April 5]. Available from: https://www.whocc.no/atc/structure_and_principles/
   Google Scholar
• Nilssen Y, Strand TE, Wiik R, et al. Utilizing national patient-register data to control for comorbidity in prognostic studies. Clin Epidemiol. 2014;6:395–404.
   PubMed Web of Science ®Google Scholar
• Yap A, Lopez-Olivo MA, Dubowitz J, et al. Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies. Br J Anaesth. 2018;121(1):45–57.
   PubMed Web of Science ®Google Scholar
• Bartlett JW, Seaman SR, White IR, et al. Multiple imputation of covariates by fully conditional specification: accommodating the substantive model. Stat Methods Med Res. 2015;24(4):462–487.
   PubMed Web of Science ®Google Scholar
• Rubin D. Multiple imputation for nonresponse in surveys. New York (NY): John Wiley and Sons; 2004.
   Google Scholar
• Kipourou DK, Charvat H, Rachet B, et al. Estimation of the adjusted cause-specific cumulative probability using flexible regression models for the cause-specific hazards. Stat Med. 2019;38(20):3896–3910.
   PubMed Web of Science ®Google Scholar
• Huang BZ, Chang JI, Li E, et al. Influence of statins and cholesterol on mortality among patients with pancreatic cancer. JNCI J Natl Cancer Inst. 2017;109(5):djw275.
   Web of Science ®Google Scholar
• Hamada T, Khalaf N, Yuan C, et al. Prediagnosis use of statins associates with increased survival times of patients with pancreatic cancer. Clin Gastroenterol Hepatol. 2018;16(8):1300–1306.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies. Clin Transl Oncol. 2019;21(6):810–816.
   PubMed Web of Science ®Google Scholar
• Moon do C, Lee HS, Lee YI, et al. Concomitant statin use has a favorable effect on gemcitabine-erlotinib combination chemotherapy for advanced pancreatic cancer. Yonsei Med J. 2016;57(5):1124–1130.
   PubMed Web of Science ®Google Scholar
• El-Refai SM, Brown JD, Arnold SM, et al. Epidemiologic analysis along the mevalonate pathway reveals improved cancer survival in patients who receive statins alone and in combination with bisphosphonates. JCO Clin Cancer Inform. 2017;1:1–12.
   PubMed Web of Science ®Google Scholar
• Gong J, Sachdev E, Robbins LA, et al. Statins and pancreatic cancer. Oncol Lett. 2017;13(3):1035–1040.
   PubMed Web of Science ®Google Scholar
• Mullen PJ, Yu R, Longo J, et al. The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer. 2016;16(11):718–731.
   PubMed Web of Science ®Google Scholar
• Guillaumond F, Bidaut G, Ouaissi M, et al. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proc Natl Acad Sci USA. 2015;112(8):2473–2478.
   PubMed Web of Science ®Google Scholar
• Souchek JJ, Baine MJ, Lin C, et al. Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation. Br J Cancer. 2014;111(6):1139–1149.
   PubMed Web of Science ®Google Scholar
• Gronich N, Rennert G. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol. 2013;10(11):625–642.
   PubMed Web of Science ®Google Scholar
• Kheloussi S. Considerations in the approach to approprate statin selection. US Pharm. 2018;43(7):22–26.
   Web of Science ®Google Scholar
• Menter DG, Ramsauer VP, Harirforoosh S, et al. Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. PLoS One. 2011;6(12):e28813.
   PubMed Web of Science ®Google Scholar
• Gbelcová H, Rimpelová S, Ruml T, et al. Variability in statin-induced changes in gene expression profiles of pancreatic cancer. Sci Rep. 2017;7:44219.
   PubMed Web of Science ®Google Scholar
• Gbelcová H, Lenícek M, Zelenka J, et al. Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer. 2008;122(6):1214–1221.
   PubMed Web of Science ®Google Scholar
• Weddle DL, Tithoff P, Williams M, et al. Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis. 2001;22(3):473–479.
   PubMed Web of Science ®Google Scholar
• Kim-Fuchs C, Le CP, Pimentel MA, et al. Chronic stress accelerates pancreatic cancer growth and invasion: a critical role for beta-adrenergic signaling in the pancreatic microenvironment. Brain Behav Immun. 2014;40:40–47.
   PubMed Web of Science ®Google Scholar
• Renz BW, Takahashi R, Tanaka T, et al. β2 adrenergic-neurotrophin feedforward loop promotes pancreatic cancer. Cancer Cell. 2018;33(1):75–90.
   PubMed Web of Science ®Google Scholar
• Shah SM, Carey IM, Owen CG, et al. Does β-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharmacol. 2011;72(1):157–161.
   PubMed Web of Science ®Google Scholar
• Springate DA, Ashcroft DM, Kontopantelis E, et al. Can analyses of electronic patient records be independently and externally validated? Study 2–the effect of β-adrenoceptor blocker therapy on cancer survival: a retrospective cohort study. BMJ Open. 2015;5(4):e007299.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya G, Babu K, Bondarde S, et al. Effect of coadministered beta blocker and COX-2 inhibitor to patients with pancreatic cancer prior to receiving albumin-bound (Nab) paclitaxel (abstract) 2015. J Clin Oncol. 2015;33(3):302.
   Web of Science ®Google Scholar
• Amin S, Boffetta P, Lucas AL. The role of common pharmaceutical agents on the prevention and treatment of pancreatic cancer. Gut Liver. 2016;10(5):665–671.
   PubMed Web of Science ®Google Scholar
• Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10(3):143–156.
   PubMed Web of Science ®Google Scholar
• Kyriacou DN, Lewis RJ. Confounding by indication in clinical research. JAMA. 2016;316(17):1818–1819.
   PubMed Web of Science ®Google Scholar
• Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med. 2010;40(11):1797–1810.
   PubMed Web of Science ®Google Scholar
• Boyd CA, Benarroch-Gampel J, Sheffield KM, et al. The effect of depression on stage at diagnosis, treatment, and survival in pancreatic adenocarcinoma. Surgery. 2012;152(3):403–413.
   PubMed Web of Science ®Google Scholar
• Schmidt-Hansen M, Berendse S, Hamilton W. Symptoms of pancreatic cancer in primary care: a systematic review. Pancreas. 2016;45(6):814–818.
   PubMed Web of Science ®Google Scholar
• Bakkevold KE, Arnesjø B, Kambestad B. Carcinoma of the pancreas and papilla of Vater: presenting symptoms, signs, and diagnosis related to stage and tumour site. A prospective multicentre trial in 472 patients. Norwegian Pancreatic Cancer Trial. Scand J Gastroenterol. 1992;27(4):317–325.
   PubMed Web of Science ®Google Scholar
• Porta M, Fabregat X, Malats N, et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol. 2005;7(5):189–197.
   PubMedGoogle Scholar
• Sørensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846–1850.
   PubMed Web of Science ®Google Scholar
• Sharma M, Holmes HM, Mehta HB, et al. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019;125(7):1155–1162.
   PubMed Web of Science ®Google Scholar
• Ben QW, Liu J, Sun YW, et al. Cigarette smoking and mortality in patients with pancreatic cancer: a systematic review and meta-analysis. Pancreas. 2019;48(8):985–995.
   PubMed Web of Science ®Google Scholar
• Shi YQ, Yang J, Du P, et al. Effect of body mass index on overall survival of pancreatic cancer: a meta-analysis. Medicine. 2016;95(14):e3305.
   PubMed Web of Science ®Google Scholar
• Li G, Taljaard M, Van den Heuvel ER, et al. An introduction to multiplicity issues in clinical trials: the what, why, when and how. Int J Epidemiol. 2017;46(2):746–755.
   PubMed Web of Science ®Google Scholar